121 related articles for article (PubMed ID: 23138165)
1. Point: Treating stage II colon cancer: the quest for personalized adjuvant care.
Vergo MT; Benson AB
J Natl Compr Canc Netw; 2012 Nov; 10(11):1370-4. PubMed ID: 23138165
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma.
Kannarkatt J; Joseph J; Kurniali PC; Al-Janadi A; Hrinczenko B
J Oncol Pract; 2017 Apr; 13(4):233-241. PubMed ID: 28399381
[TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
Benson AB; Schrag D; Somerfield MR; Cohen AM; Figueredo AT; Flynn PJ; Krzyzanowska MK; Maroun J; McAllister P; Van Cutsem E; Brouwers M; Charette M; Haller DG
J Clin Oncol; 2004 Aug; 22(16):3408-19. PubMed ID: 15199089
[TBL] [Abstract][Full Text] [Related]
4. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
5. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B
Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
7. [Adjuvant treatment for resected colon cancer].
Pointet AL; Lepère C; Taieb J
Rev Prat; 2015 Jun; 65(6):789-92. PubMed ID: 26298901
[TBL] [Abstract][Full Text] [Related]
8. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
Lieu C; Kennedy EB; Bergsland E; Berlin J; George TJ; Gill S; Gold PJ; Hantel A; Jones L; Mahmoud N; Meyerhardt J; Morris AM; Ruíz-García E; You YN; Baxter N
J Clin Oncol; 2019 Jun; 37(16):1436-1447. PubMed ID: 30986117
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant chemotherapy for colon cancer].
Dahl O
Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3094-6. PubMed ID: 18049502
[TBL] [Abstract][Full Text] [Related]
10. Recent approaches to identifying biomarkers for high-risk stage II colon cancer.
Akiyoshi T; Kobunai T; Watanabe T
Surg Today; 2012 Nov; 42(11):1037-45. PubMed ID: 22961195
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer.
Verhoeff SR; van Erning FN; Lemmens VE; de Wilt JH; Pruijt JF
Int J Cancer; 2016 Jul; 139(1):187-93. PubMed ID: 26914273
[TBL] [Abstract][Full Text] [Related]
12. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
13. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
14. New developments in the adjuvant therapy of stage II colon cancer. Risk assessments in the older patient.
McCleary NJ; Meyerhardt JA
Oncology (Williston Park); 2010 Jan; 24(1 Suppl 1):3-8. PubMed ID: 20225605
[TBL] [Abstract][Full Text] [Related]
15. Prediction of chemotherapy benefit for colon cancers.
Gilbert JA
Lancet Oncol; 2016 Mar; 17(3):e91. PubMed ID: 26831289
[No Abstract] [Full Text] [Related]
16. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
17. Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence.
You YN; Rustin RB; Sullivan JD
Surg Oncol; 2015 Jun; 24(2):61-6. PubMed ID: 25770397
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy for stage II colon cancer.
Kopetz S; Freitas D; Calabrich AF; Hoff PM
Oncology (Williston Park); 2008 Mar; 22(3):260-70; discussion 270, 273, 275. PubMed ID: 18494354
[TBL] [Abstract][Full Text] [Related]
20. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Meyerhardt JA; Heseltine D; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Thomas J; Nelson H; Whittom R; Hantel A; Schilsky RL; Fuchs CS
J Clin Oncol; 2006 Aug; 24(22):3535-41. PubMed ID: 16822843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
